Meyers Michael L. 4
4 · Syndax Pharmaceuticals Inc · Filed Jan 3, 2022
Insider Transaction Report
Form 4
Meyers Michael L.
SVP, Chief Development Officer
Transactions
- Exercise/Conversion
Common Stock
2021-12-30$8.77/sh+5,900$51,743→ 21,566 total - Exercise/Conversion
Stock Options (Right to buy)
2021-12-30−5,900→ 0 totalExercise: $8.77Exp: 2027-02-06→ Common Stock (5,900 underlying)
Footnotes (2)
- [F1]The Reporting Person is filing this Form 4 to report the acquisition of shares by the Reporting Person pursuant to the exercise of a stock option grant. There are no sales to report in this filing.
- [F2]This option is fully vested.